New RSV vaccine study targets those over 80

NCT ID NCT07203365

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Karin Karin Loré Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well the approved RSV vaccine Arexvy works in people aged 80 and older compared to those aged 60-65. Researchers will measure immune responses and side effects. The goal is to see if the vaccine protects the oldest and frailest adults as effectively as younger seniors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV IMMUNISATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RSV IMMUNISATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Akademiskt specialistcentrum Studieenheten
RECRUITING

Stockholm, 113 61, Sweden

Contact Email: •••••@•••••
Familjeläkarna SÄBO
RECRUITING

Saltsjöbaden, 13334, Sweden

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.